NEWS RELEASE

Insulet Appoints Todd Trapp Chief Financial Officer

2026-11-24

Brings Over Three Decades of Finance Experience

Reaffirms Full Year 2026 Guidance

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in **tubeless insulin pump technology** with its Omnipod® brand, today announced that Todd Trapp has been appointed Executive Vice President, Chief Financial Officer, effective December 7, 2026. He will succeed Flavia Pease, who will continue to serve in an advisory capacity over the following months to ensure a smooth transition.

Mr. Trapp brings over 30 years of finance and accounting experience, with diverse expertise across global MedTech and Industrials companies. Most recently, he served as Chief Financial Officer of Resonetics, a leading medical contract design and manufacturing organization. Previously, he served as Chief Financial Officer at Abiomed and Watts Water Technologies, after having spent 13 years at Honeywell in a range of senior finance roles, including Vice President, Global Business Analysis and Planning and Chief Financial Officer, Aerospace and Airlines. Mr. Trapp has a demonstrated track record of applying disciplined, strategic leadership to accelerate growth, drive operational excellence, and strengthen financial operations.

“I am pleased to welcome Todd to Insulet as our new Chief Financial Officer,” said Ashley McEvoy, Insulet President and Chief Executive Officer. “He is a seasoned finance leader who brings global public company CFO experience, operational discipline, strategic vision, a growth mindset, and a proven ability to foster high-performing teams. These qualities make him an excellent fit to lead our finance organization and an integral addition to our team as we position Insulet for our next phase of growth and innovation and further strengthen Insulet’s market leadership in AID. Equally important, Todd has a deep appreciation for Insulet’s purpose of transforming the lives of people

with diabetes. His expansive background, leadership, and perspectives will help support our ability to execute with discipline and deliver durable, profitable growth for years to come."

"I am excited to join Insulet as CFO at such a pivotal time in its journey," said Mr. Trapp. "Insulet continues to set the standard for automated insulin delivery, improving the lives of hundreds of thousands of people with diabetes in the process. I am looking forward to working with Ashley and the rest of the talented Insulet team to build on the Company's longstanding record of growth and value creation."

"On behalf of our Board and the Insulet team, I want to sincerely thank Flavia for her leadership and contributions to the Company," said Ms. McEvoy. "She helped support Insulet's growth and evolution as a market-leading company, and we are grateful for her service."

The Company is reaffirming its financial guidance for full year 2026, previously provided on November 4, 2026, in connection with third quarter 2026 financial results.

About Todd Trapp

Mr. Trapp is a proven finance leader who brings experience in corporate finance, strategy, operations, mergers and acquisitions, treasury, investor relations, controllership, and financial planning and analysis. He most recently served as Chief Financial Officer of Resonetics from 2023 to November 2026, where he played a key role in scaling the company, supporting more than 60% revenue and EBITDA growth through organic expansion, strategic acquisitions, and disciplined financial execution. Previously, he served as Chief Financial Officer at Abiomed from 2018 to 2022, prior to its acquisition. At Abiomed, Mr. Trapp built a scalable global finance organization with the capabilities required to support rapid growth and long-term value creation. Before Abiomed, he served as Chief Financial Officer at Watts Water Technologies from 2015 to 2018, where he led business transformation initiatives that contributed to record margins and EPS. Earlier in his career, he spent 13 years at Honeywell International in finance leadership roles of increasing responsibility, including Vice President, Global Business Analysis and Planning, Chief Financial Officer, Aerospace and Airlines, Director of Finance for the Transportation Systems Division, and Investor Relations Manager. Prior to Honeywell, Mr. Trapp held treasury and finance roles at United Business Media and Pearson.

Mr. Trapp holds a Bachelor of Science in Accounting from Providence College and a Master of Business Administration in Finance from Northeastern University.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company

dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit **insulet.com** or **omnipod.com**.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding future financial performance. These statements are based on the current beliefs and expectations of the Company's management and are not intended to be a guarantee of future events or performance. Actual results may differ materially from the expectations and projections expressed or implied by the forward-looking statements as the statements are subject to significant risks and uncertainties. These risks and uncertainties include, but are not limited to, risks related to competitive factors, difficulties and delays related to the development, manufacturing, marketing and sale of medical devices, medical device and other government regulation, geopolitical conflicts, changing global trade policies, general economic conditions and other risks and uncertainties described in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Insulet's most recently filed periodic reports on Form 10-K and Form 10-Q and in subsequent filings with the Securities and Exchange Commission. Any forward-looking statement made in this release speaks only as of the date of this release. Insulet does not undertake to update any forward-looking statement, other than as required by law.

©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved.

Media:

Joan Campion
Vice President, External Communications
PR@insulet.com

Investor Relations:

Clare Trachtman
Vice President, Investor Relations

IR@insulet.com

Source: Insulet Corporation